Safety profile and efficacy
Treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.1
Inflectra is indicated for treatment of severely active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.1
Post-marketing data of 4,393 patients has illustrated that the safety profile appears consistent with clinical studies for CT-P13 and reference infliximab, supporting the favourable risk/benefit balance for CT-P13 treatment.2
Please see the link for Inflectra® (infliximab) Prescribing Information at the top of the page, and refer to Section 4.8 for a summary of the safety profile.
Learn about the clinical evidence supporting the use of Inflectra in patients with Crohn’s disease
Learn about the dosing and administration of Inflectra in patients with Crohn’s disease
Find out more
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020